Annals On Call - First-Line Drug Therapy for Type 2 Diabetes
Authors: Robert M. Centor, Neda Laiteerapong, Aaron N. Winn
Journal: Annals of Internal Medicine (2023)

Web ExclusivesFebruary 2023Annals On Call - First-Line Drug Therapy for Type 2 DiabetesFREERobert M. Centor, MD, Neda Laiteerapong, MD, MS, and Aaron N. Winn, PhDRobert M. Centor, MDHuntsville Regional Medical Campus, University of Alabama Birmingham School of Medicine, Birmingham, Alabama (R.M.C.)Search for more papers by this author, Neda Laiteerapong, MD, MSSection of General Internal Medicine and Center for Chronic Disease Research and Policy, Department of Medicine, University of Chicago, Chicago, Illinois (N.L.)Search for more papers by this author, and Aaron N. Winn, PhDMedical College of Wisconsin, Milwaukee, Wisconsin (A.N.W.)Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/A22-0004 CME/MOC SectionsAboutVisual Abstract ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail In this episode of Annals On Call, Dr. Centor discusses the cost-effectiveness of sodium–glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists in the treatment of patients with type 2 diabetes with Drs. Neda Laiteerapong and Aaron Winn.Annals articles discussed include...First-Line Therapy for Type 2 Diabetes With Sodium–Glucose Cotransporter-2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists. A Cost-Effectiveness Study: https://www.acpjournals.org/doi/10.7326/M21-2941About Annals On CallAnnals On Call focuses on a clinically influential article published in Annals of Internal Medicine. Dr. Robert Centor shares his own perspective on the material and interviews topic area experts to discuss, debate, and share diverse insights about patient care and health care delivery.For more information on Annals On Call and for more episodes, visit go.annals.org/OnCall. Comments0 CommentsSign In to Submit A Comment Author, Article, and Disclosure InformationAffiliations: Huntsville Regional Medical Campus, University of Alabama Birmingham School of Medicine, Birmingham, Alabama (R.M.C.)Section of General Internal Medicine and Center for Chronic Disease Research and Policy, Department of Medicine, University of Chicago, Chicago, Illinois (N.L.)Medical College of Wisconsin, Milwaukee, Wisconsin (A.N.W.)Disclosures: All relevant financial relationships have been mitigated. Disclosures can be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=A22-0004.Editors' Disclosures: The editors have no relevant financial relationships to disclose. Individual forms may be viewed at www.annals.org/editorsdisclosures. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoFirst-Line Therapy for Type 2 Diabetes With Sodium–Glucose Cotransporter-2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists Jin G. Choi , Aaron N. Winn , M. Reza Skandari , Melissa I. Franco , Erin M. Staab , Jason Alexander , Wen Wan , Mengqi Zhu , Elbert S. Huang , Louis Philipson , and Neda Laiteerapong Metrics Current IssueFebruary 2023Volume 176, Issue 2 ePublished: 21 February 2023 Issue Published: February 2023 Copyright & PermissionsCopyright © 2023 by American College of Physicians. All Rights Reserved.Loading ...